StockData
Oncolytics Biotech Inc logo

Oncolytics Biotech Inc (ONCY) stock

ONCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 0/30
$0.38+0.04 (+12.53%)

Close on Nov 17, 2026Market cap $48.77MP/E –Yield –

Oncolytics Biotech r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2024 it was C$21.65M, up 22.2% from the year before. The highest annual figure on record is C$21.65M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Dec 31, 2024C$21.65M+22.2%
FY2023Dec 31, 2023C$17.71M+14.8%
FY2022Dec 31, 2022C$15.43M+19.4%
FY2021Dec 31, 2021C$12.92M-0.2%
FY2020Dec 31, 2020C$12.95M+19.7%
FY2019Dec 31, 2019C$10.82M+7.9%
FY2018Dec 31, 2018C$10.03M+6.8%
FY2017Dec 31, 2017C$9.39M-3.9%
FY2016Dec 31, 2016C$9.77M+13.6%
FY2015Dec 31, 2015C$8.60M–

More Oncolytics Biotech figures

See a number that looks wrong?